{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:39:59Z","timestamp":1762101599279},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2014,9,8]],"date-time":"2014-09-08T00:00:00Z","timestamp":1410134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>AGEs are permanently modified macromolecule derivatives that form through nonenzymatic glycation of amino groups of proteins. Glycer-AGEs are highly toxic and play an important role in the pathogenesis of chronic inflammatory diseases. However, the contribution of glycer-AGEs to the pathogenesis of uveitis is unclear. In this study, we measured serum levels of glycer-AGEs in 100 patients with endogenous uveitis (22 with HLA-B27-associated uveitis, 20 with VKH disease, 14 with Beh\u00e7et's disease, and 44 with sarcoidosis) and 33 healthy volunteers. We then examined the effect of the AGE inhibitor in a mouse model of human endogenous uveitis (EAU) by continuous oral administration of pyridoxamine at 200 or 400 mg\/kg\/day. Regardless of the etiology, serum glycer-AGE levels were significantly higher in patients with uveitis than in healthy subjects. Treatment with 400 mg\/kg pyridoxamine significantly reduced the clinical and histological severity of EAU and was accompanied by a significant decrease in serum and retinal glycer-AGE levels and suppression of translocation of NF-\u03baB p65 into the nucleus of retinal cells. Serum glycer-AGE levels may therefore serve as a biomarker of human uveitis, as well as systemic inflammation, and may contribute to the progression of uveitis, including diabetic iritis, via the activation of NF-\u03baB.<\/jats:p>","DOI":"10.1189\/jlb.3a0513-288rrr","type":"journal-article","created":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T01:22:05Z","timestamp":1410225725000},"page":"1077-1085","source":"Crossref","is-referenced-by-count":12,"title":["Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formation"],"prefix":"10.1093","volume":"96","author":[{"given":"Zhenyu","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"},{"name":"Department of Ophthalmology, Health Sciences University of Hokkaido , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiju","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyoshi","family":"Kitaichi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"},{"name":"Department of Ophthalmology, Health Sciences University of Hokkaido , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Advanced Glycation End-products Research, Department of Advanced Medicine, Kanazawa Medical University , Kanazawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Immunology, Kitasato University School of Medicine , Sagamihara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Immunology, Kitasato University School of Medicine , Sagamihara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Iwabuchi","sequence":"additional","affiliation":[{"name":"Department of Immunology, Kitasato University School of Medicine , Sagamihara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Lennikov","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuomi","family":"Mizuuchi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiro","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousuke","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Namba","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho-Ichi","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine , Kurume, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeaki","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hokkaido University Graduate School of Medicine , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,9,8]]},"reference":[{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4049\/jimmunol.140.5.1490","article-title":"A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens","volume":"140","author":"Caspi","year":"1988","journal-title":"J. Immunol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/eye.1993.55","article-title":"The Maillard or browning reaction in diabetes","volume":"7","author":"John","year":"1993","journal-title":"Eye (Lond)"},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0272-6386(00)70189-2","article-title":"Advanced glycation end products: a nephrologist's perspective","volume":"35","author":"Raj","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/bjo.85.6.746","article-title":"Advanced glycation: an important pathological event in diabetic and age related ocular disease","volume":"85","author":"Stitt","year":"2001","journal-title":"Br. J. Ophthalmol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/art.1780370517","article-title":"Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders","volume":"37","author":"Takahashi","year":"1994","journal-title":"Arthritis Rheum."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"10211","DOI":"10.1016\/S0021-9258(19)50004-7","article-title":"Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging","volume":"267","author":"Araki","year":"1992","journal-title":"J. Biol. Chem."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1074\/jbc.272.28.17810","article-title":"Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress","volume":"272","author":"Lander","year":"1997","journal-title":"J. Biol. Chem."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1016\/S0021-9258(17)36966-1","article-title":"Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors\/binding proteins","volume":"269","author":"Yan","year":"1994","journal-title":"J. Biol. Chem."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/01.ATV.14.10.1521","article-title":"Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions","volume":"14","author":"Schmidt","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev.me.42.020191.001111","article-title":"Glycosylation products as toxic mediators of diabetic complications","volume":"42","author":"Brownlee","year":"1991","journal-title":"Annu. Rev. Med."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2337\/diab.43.6.836","article-title":"Lilly Lecture 1993. Glycation and diabetic complications","volume":"43","author":"Brownlee","year":"1994","journal-title":"Diabetes"},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF03402128","article-title":"Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients","volume":"5","author":"Takeuchi","year":"1999","journal-title":"Mol. Med."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/BF03401779","article-title":"Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo","volume":"6","author":"Takeuchi","year":"2000","journal-title":"Mol. Med."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF03401969","article-title":"Immunological detection of a novel advanced glycation end-product","volume":"7","author":"Takeuchi","year":"2001","journal-title":"Mol. Med."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/1566524013363735","article-title":"Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo","volume":"1","author":"Takeuchi","year":"2001","journal-title":"Curr. Mol. Med."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.mehy.2004.03.005","article-title":"Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo","volume":"63","author":"Takeuchi","year":"2004","journal-title":"Med. Hypotheses"},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.mehy.2004.02.042","article-title":"TAGE (toxic AGEs) hypothesis in various chronic diseases","volume":"63","author":"Takeuchi","year":"2004","journal-title":"Med. Hypotheses"},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/bjo.2004.055053","article-title":"Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy","volume":"89","author":"Yokoi","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/bjo.2006.100198","article-title":"Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation","volume":"91","author":"Yokoi","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2174\/138161208784139693","article-title":"Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease","volume":"14","author":"Takeuchi","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.brainres.2006.06.038","article-title":"Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species","volume":"1108","author":"Niiya","year":"2006","journal-title":"Brain Res."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00535-007-2152-7","article-title":"Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells","volume":"43","author":"Iwamoto","year":"2008","journal-title":"J. Gastroenterol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"739852","DOI":"10.1155\/2010\/739852","article-title":"Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products","volume":"2010","author":"Takino","year":"2010","journal-title":"J. Oncol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1440-1746.2007.04943.x","article-title":"Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis","volume":"22","author":"Hyogo","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.0022-202X.2004.22218.x","article-title":"Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions","volume":"122","author":"Abe","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/bbrc.1999.0371","article-title":"Amadorins: novel post-Amadori inhibitors of advanced glycation reactions","volume":"257","author":"Khalifah","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/bbrc.1996.0366","article-title":"Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine","volume":"220","author":"Booth","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/j.1476-5381.2009.00309.x","article-title":"Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen","volume":"157","author":"Chang","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00125-004-1474-8","article-title":"Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat","volume":"47","author":"Alderson","year":"2004","journal-title":"Diabetologia"},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.metabol.2006.08.026","article-title":"Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)\/Ta mice","volume":"56","author":"Tanimoto","year":"2007","journal-title":"Metabolism"},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000095773","article-title":"Pyridoxamine inhibits maillard reactions in diabetic rat lenses","volume":"38","author":"Padival","year":"2006","journal-title":"Ophthalmic Res."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.2337\/diabetes.51.9.2826","article-title":"The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes","volume":"51","author":"Stitt","year":"2002","journal-title":"Diabetes"},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10384-009-0763-7","article-title":"Statistical analyses of ocular inflammatory diseases at Saitama Red Cross Hospital (2003\u20132007)","volume":"54","author":"Kawashima","year":"2010","journal-title":"Jpn. J. Ophthalmol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10384-006-0383-4","article-title":"Epidemiological survey of intraocular inflammation in Japan","volume":"51","author":"Goto","year":"2007","journal-title":"Jpn. J. Ophthalmol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1755-3768.2008.01282.x","article-title":"Clinical features of intraocular inflammation in Hokkaido, Japan","volume":"87","author":"Kitamei","year":"2009","journal-title":"Acta Ophthalmol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1046\/j.1365-2249.1998.00514.x","article-title":"Identification of a peptide inducing experimental autoimmune uveoretinitis (EAU) in H-2Ak-carrying mice","volume":"111","author":"Namba","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.4049\/jimmunol.165.6.2962","article-title":"Amelioration of experimental autoimmune uveoretinitis by pretreatment with a pathogenic peptide in liposome and anti-CD40 ligand monoclonal antibody","volume":"165","author":"Namba","year":"2000","journal-title":"J. Immunol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1189\/jlb.72.6.1117","article-title":"Diminution of experimental autoimmune uveoretinitis (EAU) in mice depleted of NK cells","volume":"72","author":"Kitaichi","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2174\/1389450111009011468","article-title":"Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy","volume":"11","author":"Takeuchi","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ndt\/gfm589","article-title":"Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats","volume":"23","author":"Waanders","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1523-1755.2002.00207.x","article-title":"Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat","volume":"61","author":"Degenhardt","year":"2002","journal-title":"Kidney Int."},{"key":"2023032708364444100_","first-page":"754","article-title":"T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis","volume":"39","author":"Prendergast","year":"1998","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1167\/iovs.01-1202","article-title":"Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules","volume":"44","author":"Xu","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1167\/iovs.09-4030","article-title":"Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B inhibitor dehydroxy methyl epoxyquinomicin in mice","volume":"51","author":"Iwata","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1189\/jlb.0805453","article-title":"Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate","volume":"79","author":"Kitamei","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s001250051221","article-title":"Differential accumulation of advanced glycation end products in the course of diabetic retinopathy","volume":"42","author":"Hammes","year":"1999","journal-title":"Diabetologia"},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.exger.2010.11.007","article-title":"Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes","volume":"46","author":"Yamagishi","year":"2011","journal-title":"Exp. Gerontol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00011-011-0365-y","article-title":"Inflammatory effect of advanced glycation end products on human meniscal cells from osteoarthritic knees","volume":"60","author":"Hiraiwa","year":"2011","journal-title":"Inflamm. Res."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/bjo.2005.072678","article-title":"Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease","volume":"89","author":"Kitamura","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/intimm\/8.5.799","article-title":"Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease","volume":"8","author":"Sugita","year":"1996","journal-title":"Int. Immunol."},{"key":"2023032708364444100_","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/bjo.80.11.1002","article-title":"Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease","volume":"80","author":"Norose","year":"1996","journal-title":"Br. J. Ophthalmol."}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1189%2Fjlb.3A0513-288RRR","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/96\/6\/1077\/49580607\/jlb1077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/96\/6\/1077\/49580607\/jlb1077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T12:51:32Z","timestamp":1689511892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/96\/6\/1077\/6935929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,8]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,9,8]]},"published-print":{"date-parts":[[2014,9,8]]}},"URL":"https:\/\/doi.org\/10.1189\/jlb.3a0513-288rrr","relation":{},"ISSN":["0741-5400","1938-3673"],"issn-type":[{"value":"0741-5400","type":"print"},{"value":"1938-3673","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,12]]},"published":{"date-parts":[[2014,9,8]]}}}